Methods of ascertainment of children and young people living with diabetes mellitus: a mapping exercise of National Health Service diabetic eye screening programmes

Ibanez-Bruron, Maria Carolina; Solebo, Ameenat Lola; Cumberland, Phillippa; Rahi, Jugnoo S

doi:10.1016/s0140-6736(16)32295-4

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[33,34] Therefore, effective penetration and retention delivery of ophthalmic drugs to treat eye fundus diseases requires extensive exploration. [35] Despite recent advances in ophthalmic drug delivery, achieving long-term sustained release and low ophthalmic retention remains a significant obstacle in the treatment of eye fundus diseases, such as AMD. [36][37][38][39] Difficulties arise from complex barriers in the eye, undesired release, and insufficient drug exposure of target tissues.…”

Section: Introductionmentioning

confidence: 99%

Ophthalmic Tethered Gold Yarnball‐Mediated Retained Drug Delivery for Eye Fundus Disease Treatment

Chou,

Yang,

Chiang

et al. 2024

Small Science

View full text Add to dashboard Cite

Eye fundus diseases, such as retinal degenerative diseases, which lead to blindness in ≈12% of individuals aged >65 years, cause permanent damage to retinal cells. The antioxidant quercetin (QC) is promising for the effective treatment of eye fundus diseases; however, its poor solubility and low retention rate often limit its clinical application. Herein, an in situ ophthalmic tethered gold yarnball (GY) that doubles as an ocular retention agent and QC reservoir to overcome low fundus drug retention is developed. After intravitreal injection, QC@GYs enhance retinal cell leakage and internal limiting membrane permeability, facilitating the partial penetration of QC@GYs into the intraretinal tissue. The combination of retina‐tethered QC@GY and first‐level sustained release reduces macular degeneration in vivo by effectively regulating oxidative stress. Furthermore, the sustained release of QC preserves the viability of retinal pigment epithelium cells, reduces apoptosis, and suppresses drusen formation. This preservation of retinal morphology and function maximizes the therapeutic impact while minimizing the need for frequent intraocular administration. Overall, the ophthalmic tethered GY platform is a versatile tool for retinal drug delivery for the treatment of eye fundus diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Ophthalmic Tethered Gold Yarnball‐Mediated Retained Drug Delivery for Eye Fundus Disease Treatment

Chou,

Yang,

Chiang

et al. 2024

Small Science

View full text Add to dashboard Cite

show abstract

“…The occurrence of chronic fundus oculi diseases such as diabetic retinopathy ( 1 ) and age-related macular degeneration (AMD) is continuously increasing due to the prolonged wearing of contact lenses ( 2 ), diabetes mellitus, and the increased elderly population. In recent years, many types of protein therapeutics, such as antibodies, are playing increasingly important roles in the treatment of eye diseases.…”

Section: Introductionmentioning

confidence: 99%

Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment

et al. 2023

View full text Add to dashboard Cite

Therapeutic antibodies are extensively used to treat fundus diseases by intravitreal injection, as eyedrop formulation has been rather challenging due to the presence of ocular barriers. Here, an innovative penetrating carrier was developed for antibody delivery in eyedrop formulations. We found that fluorocarbon-modified chitosan (FCS) would self-assemble with proteins to form nanocomplexes, which could effectively pass across the complicated ocular structure to reach the posterior eye segments in both mice and rabbits. In a choroidal melanoma–bearing mouse model, eyedrops containing FCS/anti-PDL1 could induce stronger antitumor immune responses than those triggered by intravenous injection of anti-PDL1. Moreover, in choroidal neovascularization–bearing mouse and rabbit models, FCS/anti-VEGFA eyedrops effectively inhibited vascular proliferation, achieving comparable therapeutic responses to those observed with intravitreal injection of anti-VEGFA. Our work presents an effective delivery carrier to treat fundus diseases using eyedrop of therapeutic proteins, which may enable at-home treatment of many eye diseases with great patient compliance.

show abstract

Liposome‐Based Permeable Eyedrops for Effective Posterior Segment Drug Delivery

Wang,

Hu,

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Topical eyedrop administration is identified as an ideal non‐invasive strategy for ocular drug delivery. However, multiple complex ocular barriers greatly restrict their effectiveness in the treatment of posterior ocular disease. Herein, a liposome‐based permeable eyedrops (pDrops) capable of overcoming multiple ocular barriers and achieving efficient posterior drug delivery is presented. pDrops have a core‐shell structure in which drugs are encapsulated inside the liposome core with a chitosan shell. This chitosan coating significantly enhances the pDrops’ binding to mucin in tears and facilitates the temporary opening of tight junctions in cornea/conjunctive epithelial cells, thereby achieving prolonged preocular retention and enhanced posterior segment drug delivery. In this study, hydrophilic ganciclovir (GCV) and hydrophobic curcumin (CUR) are employed as model drugs. Upon topical instillation, pDrops effectively overcome ocular barriers and delivered GCV to the posterior segment in both rat and rabbit eyes. Notably, CUR delivery by pDrops demonstrates significantly enhanced therapeutic efficacy in light‐damaged retina of mice. Considering that pDrops can deliver both hydrophobic and hydrophilic drugs to the posterior segment of the eye, it can potentially become a feasible platform for the non‐invasive delivery of various drug molecules and improve the treatment efficiency of posterior ocular diseases.

show abstract

Methods of ascertainment of children and young people living with diabetes mellitus: a mapping exercise of National Health Service diabetic eye screening programmes

Cited by 3 publications

References 0 publications

Ophthalmic Tethered Gold Yarnball‐Mediated Retained Drug Delivery for Eye Fundus Disease Treatment

Ophthalmic Tethered Gold Yarnball‐Mediated Retained Drug Delivery for Eye Fundus Disease Treatment

Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment

Liposome‐Based Permeable Eyedrops for Effective Posterior Segment Drug Delivery

Contact Info

Product

Resources

About